Lung Cancer
Volume 64, Issue 2 , Pages 211-218 , May 2009

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent

  • G. Carteni

      Affiliations

    • Cardarelli Hospital, Medical Oncology, Via Cardarelli 9, 80100 Naples, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0817472221; fax: +39 0817472221.
    • ,
  • C. Manegold

      Affiliations

    • Heidelberg University Medical Center, Surgery-Interdisciplinary Thoracic Oncology, Mannheim, Germany
    • ,
  • G. Martin Garcia

      Affiliations

    • University Hospital of Salamanca, Medical Oncology, Salamanca, Spain
    • ,
  • S. Siena

      Affiliations

    • Ospedale Niguarda Ca’ Granda, Divisone Oncologia Falck, Milan, Italy
    • ,
  • C.C. Zielinski

      Affiliations

    • Department of Medicine I, Medical University, Vienna, Austria
    • ,
  • D. Amadori

      Affiliations

    • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Comitato Medico-Scientifico, Meldola, Italy
    • ,
  • Y. Liu

      Affiliations

    • i3 Statprobe, Biostatistics, Austin, TX, USA
    • ,
  • J. Blatter

      Affiliations

    • Eli Lilly and Company, Medical Oncology, Bad Homburg, Germany
    • ,
  • C. Visseren-Grul

      Affiliations

    • Eli Lilly and Company, Medical Oncology, Houten, The Netherlands
    • ,
  • R. Stahel

      Affiliations

    • University Hospital, Clinic and Policlinic of Oncology, Zurich, Switzerland

Received 25 April 2008 ,Revised 7 July 2008 ,Accepted 22 August 2008.

References 

  1. Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data from 1973 through 2003. Am J Epidemiol. 2004;159:107–112
  2. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981;8:313
  3. Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005;11:982–992
  4. Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006;17:1615–1619
  5. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79(3–4):666–672
  6. DeVita V, Hellman S, Rosenberg S. Cancer: principles and practice of oncology. 7th ed.. Philadephia: Lippincott Williams & Wilkins; 2004;
  7. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67(10):999–1003
  8. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin. 2004;14:469–477
  9. Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M. Peritoneal mesothelioma. Curr Treat Options Oncol. 2000;1(4):303–312
  10. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):676–681
  11. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993;11:1559–1565
  12. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cispatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25–30
  13. Vogelzang NJ, Weissman LB, Herndon JE, Antman KH, Cooper MR, Corson JM, et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study. J Clin Oncol. 1994;12:1436–1442
  14. Le DT, Deavers M, Hunt K, Malpica A, Verschraegen C. Cisplatin and irinotecan (CPT–11) for peritoneal mesothelioma. Cancer Invest. 2003;21(5):682–689
  15. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer. 1992;65:956–960
  16. Baas P, Ardizzoni A, Grossi F, Nackaerts K, Numico G, Van Marck E, et al. EORTC Lung Cancer Group The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer. 2003;39:353–357
  17. Kindler HL, Belani CP, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the Cancer and Leukemia Group B. Cancer. 1999;89:1985–1991
  18. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18:3912–3917
  19. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta®). Oncologist. 2004;9:482–488
  20. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol. 1999;26(2 Suppl. 6):68–73
  21. European Public Assessment Report (EPAR) for authorized medical products for human use – Alimta®. European Medicines Agency (EMEA) website, <http://www.emea.europa.eu/humandocs/Humans/EPAR/alimta/alimta.htm>; 2008 [accessed 20.02.08].
  22. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644
  23. Taylor P, vonPawel J, Castagneto B, Dark G, Marangolo M, Scagliotti G, et al. Single agent pemetrexed for chemonäive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008;3(7):764–771
  24. Santoro A, O’Brien M, Stahel R, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonäive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756–763
  25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the Unites States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  26. Cancer Therapy Evaluation Program, National Cancer Institute, US National Institutes of Health. Common toxicity criteria (CTC), version 2.0, <http://ctep.cancer.gov./forms/CTCv20_4-30-992.pdf>; 2008 [accessed 18.01.08].
  27. Jänne PA, Wozniak AJ, Belani CP, Keohan M-L, Ross HJ, Polikoff JA, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40–46
  28. Karthaus M, Frieler F, Vasquez N, Grader K, Pfeil N, Plahl A, et al. Pemetrexed (A)/platinum for patients with advanced malignant peritoneal mesothelioma (AbM)—The Bielefeld experience [abstract]. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part 1, vol. 24, No. 18S (June 20 Supplement), 2006:4151.
  29. Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan M-L, Ross HJ, et al. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer. 2007;55:187–194
  30. Jänne PA, Wozniak AJ, Belani CP, Keohan M-L, Ross HJ, Polikoff JA, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1(6):506–512
  31. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443–1448

PII: S0169-5002(08)00459-5

doi: 10.1016/j.lungcan.2008.08.013

Lung Cancer
Volume 64, Issue 2 , Pages 211-218 , May 2009

Article Tools

* Image Usage & Resolution